Firefly Neuroscience, Inc. (NASDAQ: AIFF)

Firefly Neuroscience, Inc. is an Artificial Intelligence technology company focused on developing innovative neuroscientific solutions aimed at improving brain health outcomes for patients with mental illnesses and neurological disorders. The company's primary offerings include the FDA-510(k) cleared Brain Network Analytics (BNA) and the eVox System, both designed to enhance neurological assessments through objective, data-driven insights derived from EEG data. These tools are intended to aid in the early and longitudinal detection of neurophysiological deviations, thereby facilitating personalized treatment plans and improving patient outcomes more effectively than traditional EEG analysis.

Firefly Neuroscience generates revenue through two main segments. The first segment involves the use of its products by United States healthcare professionals, with a proposed business model consisting of a base service fee for licensing the product and a per-use fee based on volume. The second segment involves collaborations with pharmaceutical companies to support neuroscience drug development, with tailored business models based on volume and associated costs. The company's primary products, BNA and the eVox System, cater to a customer base that includes medical professionals such as neurologists, psychiatrists, nurse practitioners, and general practitioners, as well as pharmaceutical companies involved in drug research and clinical trials.

• Brain Network Analytics (BNA): This advanced neurophysiological assessment tool uses AI and machine learning to analyze EEG data recorded during rest and cognitive activity. The BNA Platform is designed to provide objective, data-driven insights that allow for the early and longitudinal detection of neurophysiological deviations, aiding in the tailoring of personalized treatment plans. The platform is intended for post-hoc statistical analysis of the human electroencephalogram (EEG), utilizing both resting-state EEG and Event-Related Potentials (ERP) in a patient's response to outside stimuli during various states of alertness, disease, diagnostic testing, treatment, surgery, or drug-related dysfunction. The BNA Platform consists of a computer environment, EEG data input software algorithms for BNA calculations, a report generator, and functionality for data transfer and storage. The platform processes and analyzes EEG data using Firefly's BNA Algorithm, compiling the results into individualized reports that provide clinicians with objective insight into brain electrophysiology. The BNA Platform is FDA-510(k) cleared and is intended for use in individuals aged 12 to 85 years.

• eVox System: This FDA-510(k) cleared system is intended for the acquisition, display, and storage of electrical activity of a patient's brain, including electroencephalograph (EEG) and event-related potentials (ERP) obtained by placing two or more electrodes on the head to aid in diagnosis. The eVox System has assessed approximately 100,000 scans in clinics throughout the United States.

Firefly Neuroscience holds a significant position within the neuroscientific solutions industry, particularly in the realm of EEG analysis and interpretation. The company's competitive advantages include its extensive proprietary database of standardized, high-definition longitudinal EEG recordings, which spans over 18,000 patients representing twelve disorders, as well as clinically healthy normal patients. This database, combined with advanced AI and machine learning capabilities, enables Firefly to offer unique insights into brain electrophysiology. The company's products have demonstrated real-world clinical utility, as evidenced by a study involving 2,253 patients seeking treatment at a prominent psychiatric and multispecialty clinic in the United States. The study showed improved disease management in psychiatric patients suffering from major depressive disorder (MDD), generalized anxiety disorder (GAD), and ADHD, highlighting the potential of the BNA Platform to transform psychiatric care.

The general customer base for Firefly Neuroscience includes medical professionals such as neurologists, psychiatrists, nurse practitioners, and general practitioners, as well as pharmaceutical companies involved in drug research and clinical trials. The company's products are designed to enhance neurological assessments and support better outcomes for patients with mental illnesses and cognitive disorders. Firefly Neuroscience's strategic vision and research and development efforts are focused on advancing the treatment of patients suffering from mental illnesses and cognitive disorders, with a goal of driving a better standard of care for these patients. The company's research and development team has expertise in biomedical engineering, neuroscience, software development, project management, data science, and AI and ML, which positions Firefly Neuroscience as a leader in the category of advancing the understanding of brain electrophysiology in support of better outcomes for its target patient population.